3D Medicines (HKG:1244) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥445.6m (down 30% from FY 2023).
• Net loss: CN¥182.7m (loss narrowed by 65% from FY 2023).
• CN¥0.75 loss per share (improved from CN¥2.30 loss in FY 2023).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

1244 Products In Clinical Trials

• Phase I: 5.
• Phase II: 5.
• Phase III: 3.

All figures shown in the chart above are for the trailing 12 month (TTM) period

In the last 12 months, the only revenue segment was Biopharmaceutical Research and Development contributing CN¥445.6m. The largest operating expense was Sales & Marketing costs, amounting to CN¥235.9m (39% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of CN¥52.1m. Explore how 1244's revenue and expenses shape its earnings.

3D Medicines shares are down 2.0% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on 3D Medicines' balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.